Number needed to treat for pricing costly anticancer drugs: the example of regorafenib in metastatic colorectal cancer

被引：3
作者：
Graziano, F. [1 ]
Rulli, E. [2 ]
Biagioli, E. [2 ]
Catalano, V. [1 ]
机构：
[1] Azienda Osped Osped Riuniti Marche Nord, Dept Oncohematol, Pesaro, Italy
[2] IRCCS, Ist Ric Farmacol Mario Negri, Clin Res Lab, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷 / 04期
关键词：
D O I：
10.1093/annonc/mdw024
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：747 / 748
页数：2
相关论文
共 10 条
[1]   Calculating the number needed to treat for trials where the outcome is time to an event [J].
Altman, DG ;
Andersen, PK .
BRITISH MEDICAL JOURNAL, 1999, 319 (7223) :1492-1495
[2]   Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer [J].
Goldstein, Daniel A. ;
Ahmad, Bilal B. ;
Chen, Qiushi ;
Ayer, Turgay ;
Howard, David H. ;
Lipscomb, Joseph ;
El-Rayes, Bassel F. ;
Flowers, Christopher R. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) :3727-+
[3]   Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial [J].
Grothey, Axel ;
Van Cutsem, Eric ;
Sobrero, Alberto ;
Siena, Salvatore ;
Falcone, Alfredo ;
Ychou, Marc ;
Humblet, Yves ;
Bouche, Olivier ;
Mineur, Laurent ;
Barone, Carlo ;
Adenis, Antoine ;
Tabernero, Josep ;
Yoshino, Takayuki ;
Lenz, Heinz-Josef ;
Goldberg, Richard M. ;
Sargent, Daniel J. ;
Cihon, Frank ;
Cupit, Lisa ;
Wagner, Andrea ;
Laurent, Dirk .
LANCET, 2013, 381 (9863) :303-312
[4]   Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Li, Jin ;
Qin, Shukui ;
Xu, Ruihua ;
Yau, Thomas C. C. ;
Ma, Brigette ;
Pan, Hongming ;
Xu, Jianming ;
Bai, Yuxian ;
Chi, Yihebali ;
Wang, Liwei ;
Yeh, Kun-Huei ;
Bi, Feng ;
Cheng, Ying ;
Le, Anh Tuan ;
Lin, Jen-Kou ;
Liu, Tianshu ;
Ma, Dong ;
Kappeler, Christian ;
Kalmus, Joachim ;
Kim, Tae Won .
LANCET ONCOLOGY, 2015, 16 (06) :619-629
[5]   Market Spiral Pricing of Cancer Drugs [J].
Light, Donald W. ;
Kantarjian, Hagop .
CANCER, 2013, 119 (22) :3900-3902
[6]   Economic burden of cancer across the European Union: a population-based cost analysis [J].
Luengo-Fernandez, Ramon ;
Leal, Jose ;
Gray, Alastair ;
Sullivan, Richard .
LANCET ONCOLOGY, 2013, 14 (12) :1165-1174
[7]   Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs [J].
Mailankody, Sham ;
Prasad, Vinay .
JAMA ONCOLOGY, 2015, 1 (04) :539-540
[8]   Early market access of cancer drugs in the EU [J].
Martinalbo, J. ;
Bowen, D. ;
Camarero, J. ;
Chapelin, M. ;
Demolis, P. ;
Foggi, P. ;
Jonsson, B. ;
Llinares, J. ;
Moreau, A. ;
O'Connor, D. ;
Oliveira, J. ;
Vamvakas, S. ;
Pignatti, F. .
ANNALS OF ONCOLOGY, 2016, 27 (01) :96-105
[9]   Potential Approaches to Sustainable, Long-Lasting Payment Reform in Oncology [J].
Trent, Laura .
JOURNAL OF ONCOLOGY PRACTICE, 2014, 10 (04) :254-258
[10]   Molecular profiling in the treatment of colorectal cancer: focus on regorafenib [J].
Yan, Yiyi ;
Grothey, Axel .
ONCOTARGETS AND THERAPY, 2015, 8 :2949-2957
1